Merck & Co (NYSE: MRK) Acquires Jeito Capital's EyeBio for $3 Billion
Wednesday, 29 May 2024, 08:16
Jeito Capital Announces Merck & Co's Acquisition of EyeBio for $3 Billion
Jeito Capital reveals the acquisition of its portfolio company EyeBio by Merck & Co for a potential value of $3 billion. This strategic move signifies a significant milestone in the realm of biopharmaceutical investments and mergers.
The deal is expected to have notable impacts on both companies' growth trajectories in the future.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.